Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate the interference of isatuximab when measuring levels of monoclonal protein — a marker of disease severity — in a person’s blood. Myeloma is a cancer of plasma cells, the…
For people with multiple myeloma who don’t respond well to an initial type of therapy, quickly switching to another type may improve clinical outcomes, a new study suggests. The study, “Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple…
People with monoclonal gammopathy of undetermined significance (MGUS), a rarely diagnosed condition that can progress to myeloma, go to the hospital twice as often as people without the condition, new research suggests. This may be helpful in identifying people with MGUS and, by extension, aid in early diagnosis of…
A combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone, given before and immediately after a stem cell transplant, is effective for the treatment of patients with smoldering multiple myeloma — a precursor condition to multiple myeloma — at high risk of progressing to the full…
Adding the lymphoma therapy vorinostat to Revlimid (lenalidomide) maintenance therapy may deepen responses to stem cell transplants and prolong survival outcomes in multiple myeloma patients, long-term results of a Phase 1 clinical trial show. Results were published in the journal Biology of Blood and Marrow Transplantation in…
The U.S. Food and Drug Administration (FDA) has granted its Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational therapy CT053 for the treatment of relapsed or refractory multiple myeloma. The RMAT designation is given to regenerative therapies intended to treat, modify, reverse, or cure a serious…
People with monoclonal gammopathy of undetermined significance (MGUS) placed at low- or intermediate-risk of progression to multiple myeloma can develop that cancer within five years, a study of blood serum immune markers reports. This finding warrants annual blood testing for these people, researchers wrote in the study “…
KappaMab (MDX-1097), a new monoclonal antibody that binds to the kappa myeloma antigen, has a favorable safety profile in multiple myeloma patients with excess kappa light chain, results of a pilot study suggest. The data were published in Blood Cancer Journal in a paper titled, “A preliminary…
The U.S. Food and Drug Administration (FDA) has lifted its hold on the CANOVA Phase 3 clinical trial, which is evaluating the experimental therapeutic Vencexta (venetoclax) plus dexamethasone in people with relapsed or refractory multiple myeloma who test positive for a common genetic abnormality. Venclexta (sold as Venclyxto…
Adding Darzalex (daratumumab) to the standard first-line treatment of Revlimid (lenalidomide) plus dexamethasone improves treatment and survival outcomes in multiple myeloma patients who are not eligible for an autologous stem cell transplant, a Phase 3 clinical trial shows. Findings from the MAIA trial (NCT02252172) were…
Get regular updates to your inbox.